Last reviewed · How we verify
Placebo of CKD-330
Placebo of CKD-330 is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 3 development.
This is a placebo control and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of CKD-330 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation for CKD-330, this product is inert and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active drug to maintain blinding in phase 3 studies.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (PHASE3)
- CKD-330 Phase 3 Trial in Amlodipine Non-responder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of CKD-330 CI brief — competitive landscape report
- Placebo of CKD-330 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI
Frequently asked questions about Placebo of CKD-330
What is Placebo of CKD-330?
How does Placebo of CKD-330 work?
Who makes Placebo of CKD-330?
What development phase is Placebo of CKD-330 in?
Related
- Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
- Compare: Placebo of CKD-330 vs similar drugs
- Pricing: Placebo of CKD-330 cost, discount & access